NASDAQ:ZNTL • US98943L1070
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ZENTALIS PHARMACEUTICALS INC (ZNTL).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-27 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-11-12 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-08-07 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-05-15 | Wedbush | Reiterate | Neutral -> Neutral |
| 2025-05-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-28 | Wedbush | Reiterate | Neutral -> Neutral |
| 2025-03-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-30 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-01-29 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-01-28 | UBS | Maintains | Neutral -> Neutral |
| 2024-11-15 | Guggenheim | Maintains | Buy -> Buy |
| 2024-11-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-16 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-08-12 | Wedbush | Upgrade | Underperform -> Neutral |
| 2024-08-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-20 | UBS | Downgrade | Buy -> Neutral |
| 2024-06-18 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-06-18 | Stifel | Maintains | Buy -> Buy |
| 2024-06-18 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2024-06-18 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2024-06-18 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-05-08 | Stifel | Maintains | Buy -> Buy |
| 2024-05-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-02-28 | Wedbush | Maintains | Neutral -> Neutral |
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 67.425M | -100.00% | 12.539M | 51.506M 310.77% | 165.39M 221.11% | 275.6M 66.64% | 436.34M 58.32% | 589.65M 35.14% | 708.51M 20.16% | ||||
| EBITDA YoY % growth | -225.86M -9.01% | -247.552M -9.60% | -186.169M 24.80% | -146.544M 21.28% | -165.644M -13.03% | -143.711M 13.24% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -227.29M -9.41% | -248.941M -9.53% | -187.458M 24.70% | -153.458M 18.14% | -157.151M -2.41% | -158.894M -1.11% | -156.023M 1.81% | -77.347M 50.43% | -7.862M 89.84% | 97.865M 1,344.80% | 180.54M 84.48% | 245.88M 36.19% | |
| Operating Margin | N/A | N/A | -278.02% | N/A | N/A | -1,267.20% | -302.92% | -46.77% | -2.85% | 22.43% | 30.62% | 34.70% | |
| EPS YoY % growth | -4.53 8.30% | -4.64 -2.43% | -2.28 50.86% | -2.02 11.50% | -1.90 5.67% | -1.65 13.19% | -1.37 17.13% | -0.56 59.22% | -0.13 76.26% | 0.38 384.62% | 0.99 162.16% | 1.52 53.61% |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.59 4.75% | -0.47 15.30% | -0.50 -34.85% | -0.52 -39.95% | -0.54 8.29% |
| Revenue Q2Q % growth | -100.00% | ||||
| EBITDA Q2Q % growth | -38.199M 15.06% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -36.71M 20.64% | -36.535M 0.38% | -38.102M -5.67% | -39.703M -17.69% | -41.95M -14.28% |
All data in USD
15 analysts have analysed ZNTL and the average price target is 4.9 USD. This implies a price increase of 103.15% is expected in the next year compared to the current price of 2.41.
ZENTALIS PHARMACEUTICALS INC (ZNTL) will report earnings on 2026-05-12.
The consensus EPS estimate for the next earnings of ZENTALIS PHARMACEUTICALS INC (ZNTL) is -0.59 USD and the consensus revenue estimate is 0 USD.
The number of analysts covering ZENTALIS PHARMACEUTICALS INC (ZNTL) is 15.